Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
AI in Drug Discovery: AdAlta Expands Biotech Pipeline With Octopi Network
AdAlta partners with Oktopi to integrate advanced artificial intelligence into its drug development workflows, optimizing investment and licensing decisions.
Cytomegalovirus Vaccine Development: Evaxion Unveils EVX-V1 Preclinical
Evaxion will present new preclinical data at IHW 2026 for EVX-V1, a novel AI-designed cytomegalovirus vaccine candidate addressing critical unmet needs.
Global Clinical Trials Network: Allucent Unveils IGNITE for Rapid Setup
Contract research organization Allucent launches the IGNITE network, connecting sponsors with over 250 pre-qualified sites to accelerate clinical trials.
Parkinson's Disease Treatment: Mirivadelgat Enters Phase 2a Study Trial
Foresee Pharmaceuticals' oral therapy mirivadelgat joins the Phase 2a SLEIPNIR clinical trial to evaluate ALDH2 activation for Parkinson's disease care.
New Obesity Treatment: iBio Antibody Spares Lean Mass Better Than GLP-1
Preclinical data shows iBio’s IBIO-610, a novel Activin E antibody, drives fat-selective weight loss and preserves lean mass when paired with GLP-1 drugs.
Mocaciclib CDK7 Inhibitor Extends Survival in Pediatric Brain Cancers.
Qurient’s CDK7 inhibitor mocaciclib extended survival in preclinical models of pediatric brain cancer, including medulloblastoma and AT/RT, per ISPNO 2026.
Paradigm Health Advances FDA Real-Time Clinical Trials RFI Initiatives
Paradigm Health submits its RFI response for the FDA’s Real-Time Clinical Trials initiative, aiming to accelerate biopharma trials with AI infrastructure.
FDA Approves Ready-to-Use Aprepitant Injectable Emulsion for CINV Care
The FDA approved a ready-to-use IV Aprepitant Injectable Emulsion for preventing chemotherapy-induced nausea and vomiting (CINV) without polysorbate-80.
Medical Journal Retracts Amgen's Tavneos Drug Trial After FDA Findings
The NEJM retracted a pivotal trial article for Amgen's rare-disease drug Tavneos after an FDA investigation uncovered altered patient outcome data.
FDA Reviews Sandoz Generic GLP-1s: New Tirzepatide Weight Loss Options
The FDA is reviewing Sandoz's generic tirzepatide GLP-1s for type-2 diabetes and weight management, aiming to rival Eli Lilly's Mounjaro and Zepbound.
World-First CRISPR Gene Therapy Targets Rare CTLA-4 Immune Disorders
UK scientists develop a world-first CRISPR gene therapy to treat CTLA-4 insufficiency, a devastating rare immune disorder, with trials planned for 2028.
Ionis Grants Recordati Global Rights to Zilganersen for Alexander Disease
Ionis Pharmaceuticals partners with Recordati to commercialize zilganersen for Alexander disease globally, securing a $30M upfront licensing agreement.
1
2
3
4
5
